(Q35211079)

7 August 2017

title

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study (English)

1 reference

7 August 2017

Michael Hutchinson

4

0 references

Eva Havrdová

object named as

Eva Havrdova

5

0 references

David H. Miller

1

object named as

David H Miller

1 reference

7 August 2017

Robert J Fox

2

1 reference

7 August 2017

J Theodore Phillips

3

1 reference

7 August 2017

Mariko Kita

6

1 reference

7 August 2017

Claudia A M Wheeler-Kingshott

7

1 reference

7 August 2017

Daniel J Tozer

8

1 reference

7 August 2017

David G MacManus

9

1 reference

7 August 2017

Tarek A Yousry

10

1 reference

7 August 2017

Mary Goodsell

11

1 reference

7 August 2017

Minhua Yang

12

1 reference

7 August 2017

Ray Zhang

13

1 reference

7 August 2017

Vissia Viglietta

14

1 reference

7 August 2017

Katherine T Dawson

15

1 reference

7 August 2017

CONFIRM study investigators

16

1 reference

7 August 2017

language of work or name

English

0 references

publication date

13 February 2015

1 reference

7 August 2017

1 reference

7 August 2017

volume

84

1 reference

7 August 2017

issue

11

1 reference

7 August 2017

page(s)

1145-1152

1 reference

The magnetic resonance imaging 'rule of five': predicting the occurrence of relapse

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Clinically feasible MTR is sensitive to cortical demyelination in MS.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Placebo-controlled trial of oral laquinimod for multiple sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Magnetic Resonance Techniques in Multiple Sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371413

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

26 September 2018

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis

1 reference

12 December 2020

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

1 reference

12 December 2020

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

12 December 2020

10.1212/WNL.0000000000001360

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference